Seminars in Arthritis and Rheumatism

Papers
(The H4-Index of Seminars in Arthritis and Rheumatism is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice128
mRNA vaccines in the rheumatologist's future90
Hydroxyquinone use does not increase the risk of venous thromboembolism in rheumatoid arthritis patients—Real-world evidence from a population-based cohort study75
Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative72
OMERACT validation of a deep learning algorithm for automated absolute quantification of knee joint effusion versus manual semi-quantitative assessment71
Corrigendum to “Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice” [Seminars in Arthritis and Rheumatism 71 (2025) 152640]66
Immunotherapy in cancer65
The Autoantibody response in rheumatoid arthritis; what makes it unique?64
Hidden in plain sight: Is there a crucial role for enthesitis assessment in the treatment and monitoring of axial spondyloarthritis?61
Quantification of coronary artery calcification in systemic sclerosis using visual ordinal and deep learning scoring: Association with systemic sclerosis clinical features52
Is mixed connective tissue disease (MCTD) a subtype of systemic sclerosis?51
Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis48
Factors predictive of severe thrombocytopenia and its impact on poor outcomes in Latin American patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort48
Performance of cut-offs of the ASAS Health Index to discriminate between treatment groups in patients with axial spondyloarthritis in the TICOSPA trial48
Response letter to the editor47
Looking at Fibromyalgia differently – the meaning and consequences of fibromyalgia as a dimensional disorder40
Hip and pelvis region MRI reference image atlas for scoring inflammation in peripheral joints and entheses according to the OMERACT-MRI WIPE scoring system in patients with spondyloarthritis36
Letter to the editor regarding Outcomes in patients with rheumatoid versus osteoarthritis for total hip arthroplasty: A meta-analysis and systematic review36
Response to the correspondence by Xu et al. regarding "Toward a more actionable RA-ILD risk model"35
OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF35
Survival of adults with rheumatoid arthritis associated interstitial lung disease - A systematic review and meta-analysis35
Combotherapies in immune-mediated inflammatory diseases: A study using the Clinical Data Warehouse from Paris Hospitals’ Public Assistance34
OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments34
Update on IgG4-related periaortitis/retroperitoneal fibrosis and periarteritis -recent clinical, diagnostic and therapeutic advances34
Risk prediction models for incident systemic lupus erythematosus among women in the Nurses’ health study cohorts using genetics, family history, and lifestyle and environmental factors31
Disease characteristics, co-morbidities and treatment response in a contemporary axial spondyloarthritis cohort: Analysis of 717 patients from the Greek AxSpA registry31
Imaging to predict early relapses after treatment discontinuation in patients with large vessel giant cell arteritis – A cohort study30
Using patient reported outcomes measurement information system (PROMIS®) measures in rheumatoid arthritis clinical care, research, and trials29
Corrigendum to “The Glucocorticoid Toxicity Index: Measuring Change in Glucocorticoid Toxicity Over Time” [Seminars in Arthritis and Rheumatism 55 (2022):152010]29
0.12991404533386